The bispecific anti-FGFR1/KLB agonist antibody BFKB8488A designed against it can treat obesity-related metabolic defects by specifically activating the FGFR1/KLB complex. Here, FGFR1 is linked to obesity due to melanocortin 4 receptor deficiency.